Zobrazeno 1 - 10
of 36
pro vyhledávání: '"Andrea Eisen"'
Autor:
Courtney R. Smith, Andrea Eisen, Anna M. Chiarelli, Erin B. Kennedy, Claire M. B. Holloway, Derek Muradali
Publikováno v:
Preventive Medicine. 103:70-75
There is a large and growing population of women who have a personal history of breast cancer (PHBC). This systematic review was undertaken to explore the outcomes of surveillance mammography in breast cancer survivors, and to examine the evidence fo
Autor:
T Mancuso, T Graham, Karen Ott, Paul Hewitt, Andrea Eisen, J Lorentz, M Emmerson, Jacques Raphael
Publikováno v:
Cancer Research. 76:P6-10
Background Women with identified BRCA1/2 mutation have a substantially increased risk of developing several types of cancer, mainly breast and ovarian, during their lifetime. Management options included close surveillance, chemoprevention and prophyl
Publikováno v:
Breast Cancer Research and Treatment. 152:137-145
The purpose of this study was to compare survival and risk of adverse events in women with early stage breast cancer (BC) treated with (1) doxorubicin (A), cyclophosphamide (C) + paclitaxel (P), (2) fluorouracil (F), epirubicin (E), cyclophosphamide
Autor:
Gary H. Lyman, Melinda L. Telli, Arti Hurria, Jamie N. Holloway, Neelima Denduluri, Maureen E. Trudeau, Tari A. King, Andrea Eisen, Mark R. Somerfield, Antonio C. Wolff, Ann H. Partridge
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 34(20)
Purpose A Cancer Care Ontario (CCO) guideline on the selection of optimal adjuvant chemotherapy regimens for early breast cancer including adjuvant targeted therapy for human epidermal growth factor receptor 2 (HER2)–positive breast cancers was ide
Autor:
Małgorzata Stawicka, Tomasz Byrski, Kevin Sweet, Henry T. Lynch, William D. Foulkes, Charmaine Kim-Sing, Dawna Gilchrist, Cezary Cybulski, E. Kilar, Tomasz Huzarski, Susan Armel, Ping Sun, Jacek Gronwald, Andrea Eisen, Parviz Ghadirian, Steven A. Narod, Bohdan Górski, Jan Lubinski, Susan L. Neuhausen
Publikováno v:
International Journal of Cancer. 131:229-234
Women with a BRCA1 mutation face a high lifetime risk of breast cancer. It is unknown to what extent environmental factors modify the inherent genetic risk. If women from different countries, but with similar mutations, experience different levels of
Autor:
Donald B. Plewes, Anoma Gunasekara, Petrina A. Causer, Ellen Warner, Liying Zhang, Rachel Z Bigenwald, Kimberley Hill, Sandra J. Messner, Andrea Eisen, Martin J. Yaffe, Steven A. Narod
Publikováno v:
Cancer Epidemiology, Biomarkers & Prevention. 17:706-711
Background: Several observational studies have shown that magnetic resonance imaging (MRI) is significantly more sensitive than mammography for screening women over age 25 at high risk for hereditary breast cancer; however, MRI is more costly and les
Autor:
Susan L. Neuhausen, Jacek Gronwald, Sofia D. Merajver, Barbara Pasini, Josephine Wagner Costalas, Andrea Eisen, Cezary Cybulski, Christine Rappaport, Noah D. Kauff, Aletta Poll, Carrie Snyder, Carey A. Cullinane, Howard M. Saal, Judy Garber, Joanne L. Blum, Albert E. Chudley, Gillian Mitchell, David M. Euhus, Gareth J.O. Evans, Stephanie A. Cohen, Barbara L. Weber, Siranoush Manoukian, Olufunmilayo I. Olopade, Mary B. Daly, Gad Rennert, Anna Jakubowska, Ophira Ginsburg, Tomasz Huzarski, Seema Panchal, Leigha Senter, John Lunn, Tuya Pal, Ellen Warner, Karen Glass, Susan Armel, Talia Donenberg, Robert E. Reilly, Jeffrey N. Weitzel, Taya Fallen, William D. Foulkes, Sonia Nanda, Pål Møller, Barry P. Rosen, Henry T. Lynch, Christian F. Singer, Eitan Friedman, Peter Ainsworth, Kenneth Offit, Dawna Gilchrist, Daniel Rayson, Charis Eng, Janice Little, Christine Elser, Louise Bordeleau, Wendy McKinnon, Susan T. Vadaparampil, Dana Zakalik, Dominique Stoppa-Lyonnet, Nadine Tung, Lovise Maehle, Ava Kwong, Jeanna McCuaig, Steven A. Narod, Marie E. Wood, Joanne Kotsopoulos, Kevin Sweet, Susan Hatters Friedman, Edmond G. Lemire, André Robidoux, Charmaine Kim-Sing, Fergus J. Couch, Tomasz Byrski, Claudine Isaacs, Beth Y. Karlan, Ping Sun, Rochelle Demsky, Jan Lubinski, Wendy S. Meschino, Raluca N. Kurz, Kelly A. Metcalfe
Publikováno v:
Fertility and sterility. 105(3)
Objective To evaluate the relationship between use of fertility medication (i.e., selective estrogen receptor [ER] modulator, gonadotropin, or other) or infertility treatment (i.e., IVF or IUI) and the risk of ovarian cancer among women with a BRCA1
Autor:
O.C. Freedman, Susan Dent, Maureen E. Trudeau, G.G. Fletcher, Sonal Gandhi, Andrea Eisen, Mihaela Mates
Publikováno v:
Current Oncology
Volume 22
Issue 11
Pages 2321-94
Volume 22
Issue 11
Pages 2321-94
The Program in Evidence-Based Care (pebc) of Cancer Care Ontario recently created an evidence-based consensus guideline on the systemic treatment of early breast cancer. The evidence for the guideline was compiled using a systematic review to answer
Autor:
Tara M. Friebel, Steven A. Narod, Barbara L. Weber, Ellen T. Matloff, Claudine Isaacs, Laura van 't Veer, Theresa Wagner, Henry T. Lynch, Susan L. Neuhausen, Andrea Eisen, Susan M. Domchek, D. Gareth Evans, Timothy R. Rebbeck, Rosalind A. Eeles, Mary B. Daly, Gail E. Tomlinson, Judy Garber, Katrina Armstrong, Olufunmilayo I. Olopade
Publikováno v:
Journal of Clinical Oncology. 23:7804-7810
Purpose Bilateral prophylactic oophorectomy (BPO) is widely used for cancer risk reduction in women with BRCA1/2 mutations. Many premenopausal women choose to take hormone replacement therapy (HRT) after undergoing BPO to abrogate immediate symptoms
Autor:
Steven A. Narod, Eitan Friedman, Peter Ainsworth, Gadi Rennert, Timothy R. Rebbeck, Henry T. Lynch, William D. Foulkes, Ruth Gershoni-Baruch, Pål Møller, Andrea Eisen, Parviz Ghadirian, Kenneth Offit, Claudine Isaacs, Susan L. Neuhausen, Barbara L. Weber, Jan Klijn, Jan Lubinski, Ping Sun, Teresa Wagner, Charmaine Kim-Sing
Publikováno v:
Journal of Clinical Oncology. 23:7491-7496
Purpose The purpose of this study was to estimate the extent of protection offered against breast cancer by prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations and to determine to what extent risk reduction varies with age at oophorecto